NANOG as an adverse predictive marker in advanced non–small cell lung cancer treated with platinum-based chemotherapy
Boksoon Chang(Kyung Hee University), Seung Hyeun Lee(Kangwon National University)
Cited by 23
Related Papers
Safety and Efficacy of Bojungikki-Tang in Advanced NSCLC Patients Receiving Treatment with Immune Checkpoint Inhibitors: Protocol for a Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Trial
|International Journal of Environmental Research and Public Health|2023|7
Efficacy and Safety of Herbal Medicine Bojungikki-Tang in Combination with Pembrolizumab versus Pembrolizumab Monotherapy for Stage IV Non-Small Cell Lung Cancer: Study Protocol for a Randomized, Open-Label, Double-Arm, Multicenter Trial
|Integrative Cancer Therapies|2025|6
M2a Macrophage-Dominant Microenvironment in Inflammation Attenuation and Wound Healing of Human Corneal Endothelial Cells
|Investigative Ophthalmology & Visual Science|2025|6
Efferocytosis by Macrophages Attenuates Inflammatory Responses Following Ultraviolet B-Induced Apoptosis in Corneal Stromal Cells
|Investigative Ophthalmology & Visual Science|2025|3